Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Context Therapeutics Inc.NASDAQ: CNTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $7.02M rose 102.6% year over year, ahead of the +46.4% change in trailing-twelve-month research & development. Sequentially, it fell 40.8% from the prior quarter. Over 3 fiscal years it compounded at +65.0% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +102.6% holds above the trailing-twelve-month pace of +46.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.02M-40.8% QoQ
Last fiscal yearDec 2025
$31.86M+40.3% YoY
LTMMar 2026
$35.41M+46.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+102.6%——
1 year+40.3%——
3-year CAGR+65.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
31.86M USD
Year-over-year change
+40.3%
4-year CAGR
+70.1%

Research & Development vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +46.4% is the 2nd highest of 11, against a peer median of -18.9%.
  • Over three fiscal years its annual growth of +65.0% compares with a peer median of -18.0%.
CNTX Competitors
Research & Development for CNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
WHWKWhitehawk Therapeutics IncLTM Mar 2026$99.41M USD+115.1%+40.7%—
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M USD+29.2%-26.9%59059.4%
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M USD-40.4%-24.8%3629.9%
CNTXContext Therapeutics Inc.LTM Mar 2026$35.41M USD+46.4%+65.0%—
KLRSKalaris Therapeutics IncLTM Mar 2026$32.3M USD-29.1%+37.8%—
IMAImageneBio IncLTM Mar 2026$30.77M USD+23.4%-23.7%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M USD-8.9%+1.3%422.2%
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
CLNNClene Inc.LTM Mar 2026$12.86M USD-17.9%-24.0%9596.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M USD-21.5%-38.7%—
Peer median (excluding CNTX) —-18.9%-18.0%6613.1%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.81M7.09M17.78M22.7M31.86M
Selling, General & Admin3.63M7.79M7.29M7.22M7.85M
Operating Expenses10.53M15.38M25.07M29.92M39.7M
Depreciation & Amortization09.27K12.04K10.88K16.25K
EBITDA(7.44M)(14.87M)(23.95M)(26.71M)(36.11M)
EBITDA Margin—————
Operating Income(10.53M)(15.38M)(25.07M)(29.92M)(39.7M)
Operating Margin—————
Interest Income64547.27K1.16M3.2M3.38M
Interest Expense64.24K547.27K000
Other Income / Expenses68.95K545.26K1.11M3.2M3.58M
Income Before Tax(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Net Margin—————
EPS (Basic)(3.69)(0.93)(1.50)(0.46)(0.38)
EPS (Diluted)(3.69)(0.93)(1.50)(0.46)(0.38)
Weighted Avg Shares2.83M15.97M15.97M58.42M95.19M
Weighted Avg Shares (Diluted)2.83M15.97M15.97M58.42M95.19M

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.